Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions			1 Months Ended			12 Months Ended
	Jan. 29, 2024 USD ($) $ / shares shares	Jan. 01, 2024 USD ($)	Jun. 30, 2023 USD ($) Program	May 31, 2023 USD ($) Program	Oct. 31, 2022	Dec. 31, 2023 USD ($) Program $ / shares shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) Program shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2017 USD ($)	Jan. 31, 2024
Related Party Transaction [Line Items]
Issuance of common stock						$ 25.0		$ 220.0
Taiho Agreement | Taiho Pharmaceutical Co., Ltd
Related Party Transaction [Line Items]
Payment for option exercise						$ 28.0
Taiho Agreement | Subsequent Event | Taiho Pharmaceutical Co., Ltd
Related Party Transaction [Line Items]
Payment for option exercise		$ 26.0
Maximum | Taiho Agreement | Taiho Pharmaceutical Co., Ltd
Related Party Transaction [Line Items]
Payment for option exercise										$ 15.0
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held						19.60%
Related Party | Subsequent Event
Related Party Transaction [Line Items]
Percentage of outstanding common stock held											33.10%
Related Party | Research and Development
Related Party Transaction [Line Items]
Net of recoveries from related party for shared costs						$ 110.0	$ 132.0	$ 25.0
Related Party | General and administrative
Related Party Transaction [Line Items]
Net of recoveries from related party for shared costs							1.0
Related Party | Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs									10 years
Gilead | Third Stock Purchase Agreement Amendment | Subsequent Event
Related Party Transaction [Line Items]
Issuance of common stock (in shares) | shares	15.2
Issuance of common stock	$ 320.0
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares	$ 21.00
Common Stock Purchase Agreement | Related Party
Related Party Transaction [Line Items]
Issuance of common stock (in shares) | shares						1.0		5.7	6.0
Funds received for stock purchase agreement									$ 200.0
Purchase price of common stock allocation to performance obligation									91.0
Issuance of common stock						$ 20.0		$ 220.0
Percentage of premium purchase price of common stock						20.00%
Trailing days average closing price						5 days
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares						$ 33.54
Common Stock Purchase Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage						35.00%
Amended Investor Rights Agreement
Related Party Transaction [Line Items]
Lockup period					2 years
Extended lockup period					3 years
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities						$ 60.0
Option payment upon achievement of certain development milestones						$ 150.0
Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Option continuation payment due upon eighth anniversary of agreement									100.0
Option continuation payment due upon fourth anniversary of agreement									100.0
Option continuation payment due upon second anniversary of agreement									100.0
Option continuation payment due upon sixth anniversary of agreement									100.0
Upfront cash payment									$ 175.0
Option fee per program for all other programs entering clinical development to exercise option								150.0
Number of research programs | Program						2
Licensing revenue recognized						$ 112.0	$ 107.0	361.0
Gilead Collaboration Agreement | Related Party | Subsequent Event
Related Party Transaction [Line Items]
Option continuation payment due upon fourth anniversary of agreement	$ 100.0
Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab								$ 500.0
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | Program								3
Option payments received								$ 725.0
Removal of option continuation payment under agreement								$ 100.0
Option payment upon achievement of certain development milestones				$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | Program				2,000,000
Amended Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Upfront cash payment			$ 35.0	$ 17.5
Number of research programs | Program			2
Option payment upon completion of certain IND-enabling activities				45.0
Amended Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received				$ 375.0